By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Calling Affymetrix a "turnaround story," investment firm Mizuho Securities initiated coverage of the microarray firm with an Outperform rating and a price target of $6 per share.

In a research report published Thursday, analyst Peter Lawson estimated Affy's 2011 loss per share at $.06 on revenues of $275.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.